Lyell Immunopharma, Inc.
LYEL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15 | $8 | $7 | $11 |
| % Growth | 87.5% | 14.3% | -36.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $15 | $8 | $7 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $28,172 | $34,857 | $43,447 | $48,668 |
| G&A Expenses | $10,687 | $9,786 | $14,046 | $14,522 |
| SG&A Expenses | $10,687 | $9,786 | $14,046 | $14,522 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,591 | $2,505 | -$119 | $137,968 |
| Operating Expenses | $37,268 | $47,148 | $57,374 | $201,158 |
| Operating Income | -$37,253 | -$47,140 | -$57,367 | -$201,147 |
| % Margin | -248,353.3% | -589,250% | -819,528.6% | -1,828,609.1% |
| Other Income/Exp. Net | -$1,593 | $4,456 | $5,172 | $9,212 |
| Pre-Tax Income | -$38,846 | -$42,684 | -$52,195 | -$191,935 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$38,846 | -$42,684 | -$52,195 | -$191,935 |
| % Margin | -258,973.3% | -533,550% | -745,642.9% | -1,744,863.6% |
| EPS | -2.13 | -2.89 | -0.18 | -0.72 |
| % Growth | 26.3% | -1,505.6% | 75% | – |
| EPS Diluted | -2.13 | -2.89 | -0.18 | -0.72 |
| Weighted Avg Shares Out | 18,268 | 14,793 | 14,755 | 13,327 |
| Weighted Avg Shares Out Dil | 18,268 | 14,793 | 14,755 | 13,327 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,266 | $3,276 | $3,862 | $4,920 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $2,566 | $3,135 | $3,441 | $5,026 |
| EBITDA | -$36,280 | -$42,562 | -$53,926 | -$57,640 |
| % Margin | -241,866.7% | -532,025% | -770,371.4% | -524,000% |